Dipongkor Saha and colleagues in 2018 GBM may be treated with oHSV immunoviral therapy in combination with two checkpoint inhibitors (anti-PD-1 and anti-CTLA-4), a triple combination that could assist in curing less immunogenic malignancies such as GBM (31). Here, CTLA4 is linked to glioblastoma.